Abstract: Methods and systems for sample contamination detection are disclosed. In particular, sample barcodes are utilized, wherein each sample barcode is assigned to a sample and ligated to fragments from the sample. The sample barcodes are used in conjunction with indices from sequencing libraries to accurately assign sequence reads to samples during multiplex sequencing. Molecule identifiers may also be utilized to aid in de-duping of sequence reads to precisely identify original NA fragments from a sample. Accordingly, in one or more embodiments, a sequencing method includes isolating DNA fragments in a sample, ligating the DNA fragments with unique molecule identifiers (UMIs), performing an amplification process resulting in amplicons, ligating a sample barcode onto the amplicons, and performing amplicon sequencing. The analytics system looks to whether indices are matched and whether a sample barcode matches to the pair of indices when identifying single-index or double-index hopping events.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

Abstract: A mouth insert for treating nosebleeds includes a main body and a bite tab. The bite tab removably engages the main body and is configured to move up and/or down vertically in order to adjust the height of the device. The main body includes a horizontally extending elongated portion, a center portion extending downward from a bottom surface of the elongated portion, and the center portion has a narrower width than the horizontally extending elongated portion. The elongated portion of the main body is shaped and dimensioned to be inserted into a buccal cavity of a user's mouth and to fit behind the user's upper lip and in front of the user's upper gums, and the center portion is shaped and dimensioned to be positioned only in front of the user's upper front teeth.

Abstract: In comparison to conventional sequencing pileup algorithms, the process described herein generates sequencing pileups that contains additional information not typically reported by conventional algorithms while also consuming fewer computational resources (e.g., time, processing power, and memory). First, each of a FASTA reference genome and BAM sequence read files are converted to an internal representation. This enables the rapid iteration across nucleotide bases of the sequence reads to determine support characteristics that summarize information of nucleic acid molecules corresponding to positions across the reference genome. Next, the support characteristics of positions across the reference genome are stored through a memory allocation process that utilizes a first and a second temporary storage. This enables the convenient freeing of one temporary storage while the other temporary storage is being used.

Abstract: Methods and systems for detecting contaminated fragments in a biological sample for cancer classification are disclosed. The system identifies CpG-SNP contamination markers. The CpG-SNP contamination markers include at least one SNP that affects a CpG site. The CpG-SNP contamination markers may include additive CpG-SNP sites and/or subtractive CpG-SNP sites. Additive CpG-SNP sites include an SNP that creates a new CpG site. Subtractive CpG-SNP sites include an SNP that removes a preexisting CpG site. Hybrid sites may include additional sites. A multiple CpG-SNP contamination marker comprises two or more CpG-SNP sites. A CpG-SNP & indel contamination marker comprises at least one CpG-SNP site and an indel site. For a given sample, the system identifies contamination markers for which the sample is homozygous. The system determines fragments having a haplotype that is different from the homozygous haplotype of the sample to be contamination fragments.

Abstract: Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: A mouth insert for treating nosebleeds includes a main body and a bite tab. The bite tab removably engages the main body and is configured to move up and/or down vertically in order to adjust the height of the device. The main body includes a horizontally extending elongated portion, a center portion extending downward from a bottom surface of the elongated portion, and the center portion has a narrower width than the horizontally extending elongated portion. The elongated portion of the main body is shaped and dimensioned to be inserted into a buccal cavity of a user's mouth and to fit behind the user's upper lip and in front of the user's upper gums, and the center portion is shaped and dimensioned to be positioned only in front of the user's upper front teeth.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: An allelic position variant calling method using a prior genotype probability at the allelic position is provided. A strand specific base count set in forward and reverse directions for the allelic position is obtained, using strand orientation and identity of a respective base at the allelic position in each respective nucleic acid fragment sequence that maps to the allelic position, where bases at the allelic position whose identity can be affected by conversion of cytosine to uracil do not contribute to the strand specific base count set. Respective forward and reverse strand conditional probabilities are computed for each candidate genotype for the allelic position using the strand specific base count set and sequencing error estimate. Likelihoods are computed using a combination of these conditional probabilities and the prior genotype probability. From this, a determination is made as to whether the likelihoods support a variant call at the allelic position.

Abstract: Systems and methods for determining consensus base calls in nucleic acid sequencing are provided. A sequencing dataset is obtained corresponding to a plurality of base reads for a first base position within a plurality of base positions of a target nucleic acid molecule. The sequencing dataset includes at least two features, for each base read of the plurality of base reads. The at least two features are selected from among the features: a nucleotide base, a read quality score, a strand identifier, a trinucleotide context of the base read, and a confidence score associated with the trinucleotide context. The sequencing dataset is transformed into a feature tensor representing a distribution of the plurality of features in the sequencing dataset. The feature tensor is assessed with a classifier to determine a consensus base call for the first base position. The consensus base call comprises a predicted nucleotide base.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

Abstract: Described herein are methods and systems for the detection of anti-vinculin antibodies, for determining a presence or likely presence of a gastrointestinal motility disorder, bladder motility disorder, or fibromyalgia. Further provided are methods of selecting and/or administering a therapy based on the presence or absence of anti-vinculin antibodies.

Abstract: The present invention describes methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering CDT inhibitors and/or CDT neutralizers to a subject in need thereof. The present invention also describes methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS. The present invention further describes methods of diagnosing IBS by detecting the presence or absence of CDT or a CDT marker in a subject.

Abstract: There is provided an apparatus which can include a plurality of speaker drivers and a control processor. The control processor can be configured to flexibly group the speaker drivers. The control processor can be further configured to perform the tasks of controlling directivity of audio output from at least one group and providing time delay to audio output from at least one speaker driver from at least one controlled group so as to generate at least one sound field associable with a dispersed profile.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: Described herein are methods and systems for distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-vinculin antibodies and anti-CdtB antibodies to distinguish IBS from IBD and celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.